<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3,938</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2021</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">21</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.alkRearrangement<br/><br/>

<div class='content chap10-para-head'><strong>Description</strong></div>
<div class='content chap10-para'>
<p>Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors.</p>

</div>

<div class='content chap10-para-head'><strong>Rationale</strong></div>
<div class='content chap10-para'>
<p>ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.</p>

</div>



<div class='content chap10-para'><p><strong>Codes</strong></p>
</div>
<table>
        <tr class='code-row'><td class='code-nbr'>0</td><td class='code-desc'>Normal  
 ALK negative  
 Negative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected</td></tr>
        <tr class='code-row'><td class='code-nbr'>1</td><td class='code-desc'>Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK</td></tr>
        <tr class='code-row'><td class='code-nbr'>2</td><td class='code-desc'>Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1</td></tr>
        <tr class='code-row'><td class='code-nbr'>4</td><td class='code-desc'>Rearrangement, NOS</td></tr>
        <tr class='code-row'><td class='code-nbr'>7</td><td class='code-desc'>Test ordered, results not in chart</td></tr>
        <tr class='code-row'><td class='code-nbr'>8</td><td class='code-desc'>Not applicable: Information not collected for this case  
 If this information is required by your standard setter, use of code 8 may result in an edit error.</td></tr>
        <tr class='code-row'><td class='code-nbr'>9</td><td class='code-desc'>Not documented in medical record  
 ALK Rearrangement not assessed or unknown if assessed</td></tr>
        <tr class='code-row'><td class='code-nbr'>Blank</td><td class='code-desc'>Diagnosis year is prior to 2021</td></tr>
</table>

<div class='content chap10-para'>
<p>Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.</p>

</div>
